CLINICAL TRIALS PROFILE FOR DEUTETRABENAZINE

All Clinical Trials for deutetrabenazine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01795859 ↗	First Time Use of SD-809 in Huntington Disease	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3	2013-08-05	The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
NCT01795859 ↗	First Time Use of SD-809 in Huntington Disease	Completed	Teva Pharmaceutical Industries	Phase 3	2013-08-05	The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
NCT01897896 ↗	Alternatives for Reducing Chorea in Huntington Disease	Completed	Auspex Pharmaceuticals, Inc.	Phase 3	2013-11-12	The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.
NCT02195700 ↗	Aim to Reduce Movements in Tardive Dyskinesia	Completed	Auspex Pharmaceuticals, Inc.	Phase 2/Phase 3	2014-06-01	The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
NCT02198794 ↗	Reducing Involuntary Movements in Participants With Tardive Dyskinesia	Completed	Auspex Pharmaceuticals, Inc.	Phase 3	2014-10-20	The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.
NCT02291861 ↗	Addressing Involuntary Movements in Tardive Dyskinesia	Completed	Auspex Pharmaceuticals, Inc.	Phase 3	2014-10-31	The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Clinical Trial Conditions for deutetrabenazine

Condition Name

Condition Name for deutetrabenazine
Intervention	Trials
TOURETTE SYNDROME	4
Huntington Disease	3
Tardive Dyskinesia	3
Cerebral Palsy, Dyskinetic	2

Condition MeSH

Condition MeSH for deutetrabenazine
Intervention	Trials
Huntington Disease	5
Dyskinesias	4
Tourette Syndrome	4
Syndrome	4

Clinical Trial Locations for deutetrabenazine

Trials by Country

Trials by Country for deutetrabenazine
Location	Trials
United States	189
Canada	7
Poland	7
Russian Federation	4
Australia	4

Trials by US State

Trials by US State for deutetrabenazine
Location	Trials
Texas	10
Tennessee	10
Missouri	9
Florida	9
Alabama	9

Clinical Trial Progress for deutetrabenazine

Clinical Trial Phase

Clinical Trial Phase for deutetrabenazine
Clinical Trial Phase	Trials
Phase 3	8
Phase 2/Phase 3	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for deutetrabenazine
Clinical Trial Phase	Trials
Completed	8
Recruiting	5
Not yet recruiting	1

Clinical Trial Sponsors for deutetrabenazine

Sponsor Name

Sponsor Name for deutetrabenazine
Sponsor	Trials
Teva Branded Pharmaceutical Products R&D, Inc.	8
Teva Branded Pharmaceutical Products, R&D Inc.	6
Auspex Pharmaceuticals, Inc.	5

Sponsor Type

Sponsor Type for deutetrabenazine
Sponsor	Trials
Industry	23
Other	4